Posted by Michael Wonder on 29 Nov 2023
Karuna Therapeutics announces US FDA accepts new drug application for KarXT for the treatment of schizophrenia
29 November 2023 - PDUFA action date is 26 September 2024.
Karuna Therapeutics today announced the US FDA has accepted its new drug application for KarXT (xanomeline-trospium) for the treatment of schizophrenia in adults.
